Childhood cancers trials in China

In China 608 Also abroad 2459

608 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Beijing
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Beijing, Chengdu, Guangzhou, Shanghai
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 3Taking people
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Where
Beijing, Changde, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou, Linyi, Luzhou, Nanchang, Shandong, Shanghai, Shenyang, Shenzhen, Tianjin, Wuhan, Xi'an, Yibin, Yinchuan, Zhengzhou, Zhuzhou
Age
15 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00
Phase 2Taking people
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Where
Tianjin, Zhengzhou
Age
1 year to 18 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07354074
Phase 1Taking people
CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Where
Beijing
Age
14 years to 75 years
People
12
Run by
Liping Dou
See details and how to joinNCT07927816
Phase 1Taking people
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Where
Beijing, Chengdu, Guangdong, Hangzhou, Nanjing, Shanghai, Shenyang, Shijiazhuang, Xian, Zhengzhou
Age
12 years and over
People
276 worldwide
Run by
Abbisko Therapeutics Co, Ltd
See details and how to joinNCT04192344
Phase 4Taking people
Asciminib Roll-over Study
Where
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Xian, Zhengzhou
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
No phaseTaking people
Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Bladder Cancer
Where
Chongqing
People
2,000
Run by
Mingzhao Xiao
See details and how to joinNCT06389019
No phaseEnrolling by invitation
Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
Where
Shanghai
People
40
Run by
RenJi Hospital
See details and how to joinNCT07833046
Phase 3Taking people
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Where
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Meizhou, Nanchang, Nanjing, Shanghai, Tianjin, Wuhan, Xiamen, Xi'an, XI 'an City, Shaanxi Province, Xinxiang, Zhengzhou
People
200 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05862285 · EU 2023-504263-16-00
No phaseTaking people
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Where
Fuzhou
People
100
Run by
Fujian Medical University Union Hospital
See details and how to joinNCT07920770
No phaseNot yet taking people in China
Automated Radiation Target Contouring and Treatment Planning Via RATA: A Multi-Center RCT
Where
Guangzhou
People
62
Run by
zhaoxiaohui
See details and how to joinNCT07922902
Phase 1/2Taking people
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Chengdu, Guangzhou, Nanning
Age
6 months to 30 years
People
65 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05533775
No phaseTaking people
Study of Anxiety and Depression in Patients With Hematologic Malignancies
Where
Xiamen
People
100
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT07883070
No phaseNot yet taking people in China
Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
Where
Beijing
Age
14 years to 65 years
People
180
Run by
Peking University People's Hospital
See details and how to joinNCT07919470
Phase 1/2Taking people
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Where
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wenzhou, Wuhan, Zhengzhou
Age
2 years and over
People
420 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00
No phaseNot yet taking people in China
Multi-center Prospective Validation of Real-Time AI-EGGIM System
Where
Binzhou, Jinan, Qingdao
People
540
Run by
Qilu Hospital of Shandong University
See details and how to joinNCT07915843
No phaseTaking people
Retroperitoneal Tumor Registry
Where
Changchun
People
200
Run by
The First Hospital of Jilin University
See details and how to joinNCT07915895
Phase 1/2Not yet taking people in China
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Where
Shenzhen
Age
2 years to 75 years
People
10
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03222674
Phase 1/2Enrolling by invitation
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
Where
Shenzhen
Age
10 years to 80 years
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03393962
Phase 1/2Not yet taking people in China
Immunotherapy Treating GI Cancer
Where
Shenzhen
Age
1 year to 80 years
People
100
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03614650
Phase 1/2Not yet taking people in China
CAR-T Immunotherapy Targeting CD19- ALL
Where
Shenzhen
Age
6 months to 75 years
People
100
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04016129
Phase 1/2Not yet taking people in China
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04033302
Phase 1/2Not yet taking people in China
Multi-CAR-T Cells Targeting B Cell Lymphomas
Where
Shenzhen
Age
6 months to 75 years
People
11
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04429438
Phase 1/2Not yet taking people in China
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276
Where
Shenzhen
Age
1 year to 75 years
People
100
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04432649